Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 469 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Regulatory Clear all
Completed Phase 1Phase 2 Interventional

Liver Transplantation With Tregs at MGH

NCT03577431
View directory record Official record
Conditions
Liver Transplant
Interventions
arTreg-CSB, leukapheresis, cyclophosphamide, mesna, everolimus
Biological · Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Not applicable Interventional

Empowered Relief for Youth

NCT05998369
View directory record Official record
Conditions
Chronic Pain, Musculoskeletal Pain, Fibromyalgia, Neuropathic Pain, Complex Regional Pain Syndromes, Abdominal Pain
Interventions
Empowered Relief for Youth
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Regulating Efficacy and Wellness in Diabetes

NCT01790724
View directory record Official record
Conditions
Diabetes Type 2, Metabolic Syndrome
Interventions
Walking exercise
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
50 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT03927105
View directory record Official record
Conditions
Peripheral T Cell Lymphoma
Interventions
Nivolumab, cabiralizumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Ann Arbor, Michigan • Columbus, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

NCT01568866
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Bortezomib, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
27
States / cities
Burbank, California • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Not applicable Interventional

Omega-3 Replacement With Krill Oil in Disease Management of SLE

NCT03626311
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
AKBM-3031, Placebo
Dietary Supplement · Other
Lead sponsor
Aker BioMarine Human Ingredients AS
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Phase 1 Interventional

T Cell Effector and Regulatory Mechanisms in Asthma

NCT01612936
View directory record Official record
Conditions
Asthma, Allergies
Interventions
Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage, PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
Biological · Procedure
Lead sponsor
Andrew D. Luster, M.D.,Ph.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 23, 2026, 1:12 AM EDT
Not yet recruiting Not applicable Interventional

Clinical Outcomes of Root Canal Treatment Using Modern Irrigation Protocols

NCT07852312
View directory record Official record
Conditions
Pulp Disease, Dental
Interventions
GentleWave®, EdgePRO™, Fotona LightWalker®, Conventional Needle Irrigation
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Phase 3 Interventional

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)

NCT04037397
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Anti Arrhythmics, Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation
Drug · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Tucson, Arizona • The Bronx, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 23, 2026, 1:12 AM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

NCT01307618
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Skin Melanoma
Interventions
NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12, MART-1 Antigen, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 23, 2026, 1:12 AM EDT
Enrolling by invitation No phase listed Observational

Healthcare Integrity & Anti-Fraud Enforcement

NCT07217730
View directory record Official record
Conditions
Healthcare Fraud Schemes, Kickback Networks, Supply Chain Vulnerabilities, Governance Failures, Whistleblower Activation, Regulatory Escalation Pathways, Validator Oversight & DAO Governance, Public Transparency & Auditability
Interventions
Validator-Governed Reform & Regulatory Escalation Protocol, Coalition-Grade Validator Dashboard Module (CVDM-1), Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)
Other · Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Phase 4 Interventional Results available

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

NCT01789281
View directory record Official record
Conditions
Neoplasms
Interventions
Everolimus, Sandostatin LAR Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
13
States / cities
Little Rock, Arkansas • Greenwood Village, Colorado • Stamford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Strategic Management to Optimize Response To Cardiac Resynchronization Therapy

NCT03089281
View directory record Official record
Conditions
Heart Failure
Interventions
CRT-D
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 23, 2026, 1:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Anatomical and Functional Imaging Correlates of Chronic Pain in Cerebral Palsy

NCT05197946
View directory record Official record
Conditions
Cerebral Palsy, Chronic Pain
Interventions
MRI
Diagnostic Test
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 1:12 AM EDT
Active, not recruiting Phase 1 Interventional

ABA-101 in Participants With Progressive Multiple Sclerosis

NCT06566261
View directory record Official record
Conditions
Progressive Multiple Sclerosis
Interventions
ABA-101
Biological
Lead sponsor
Abata Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Baltimore, Maryland • New Brunswick, New Jersey • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 23, 2026, 1:12 AM EDT
Active, not recruiting Phase 2 Interventional

T-regulatory Cells in ALS

NCT04055623
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

NCT01014988
View directory record Official record
Conditions
Influenza, Human
Interventions
zanamivir aqueous solution
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Diaphragmatic Breathing and Heart Rate Variability Training for Improving Hypertension in Fragile X Associated Tremor/Ataxia

NCT03816540
View directory record Official record
Conditions
Hypertension, FXTAS
Interventions
HRV and respiratory coherence biofeedback
Device
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 23, 2026, 1:12 AM EDT
Not yet recruiting No phase listed Observational

Retrospective Kinetic Safety Evaluation of an Intravenous Micellar Excipient Platform

NCT07609069
View directory record Official record
Conditions
Drug Related Side Effects and Adverse Reactions, Infusion Reactions
Interventions
PIV-850 (850-picometer Dual-NCE Acidic Matrix), Legacy Heterogeneous Payload (Micellar Vehicle)
Drug
Lead sponsor
PICO IV, Inc.
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Phase 1 Interventional

Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )

NCT02244801
View directory record Official record
Conditions
Kidney Disease
Interventions
darTreg infusion
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Not applicable Interventional Results available

Improving Treatment Outcomes for Suicidal Veterans With PTSD

NCT04690582
View directory record Official record
Conditions
Suicidal Ideation, Suicide, Attempted, Ptsd
Interventions
Cognitive Processing Therapy (CPT), Crisis Response Plan (CRP), Safety Planning Intervention (SPI), Narrative Assessment
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Potential Effects of Electronic Nicotine Delivery System Flavor Regulations on African American Menthol Smokers

NCT05023096
View directory record Official record
Conditions
Electronic Nicotine Delivery System Flavors
Interventions
Tobacco product administration and assessment
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 23, 2026, 1:12 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of Low Level Laser Therapy on Pain Induced by Placement of Orthodontic Separators in Pediatric Patients

NCT02211547
View directory record Official record
Conditions
Levels of Pain
Interventions
Epic 10 Diode Laser by Biolase Inc., Placebo
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 23, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

NCT00089609
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Thalidomide, Prednisone, bevacizumab, polymorphism analysis, immunoenzyme technique, laboratory biomarker analysis, pharmacological study
Drug · Biological · Genetic + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 23, 2026, 1:12 AM EDT